|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Bone Diseases
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Autosomal dominant osteopetrosis type II (ADO-II) is a heritable bone disorder characterized by osteosclerosis, predominantly involving the spine (vertebral end-plate thickening, or rugger-jersey spine), the pelvis ("bone-within-bone" structures) and the skull base.
|
26056022 |
2016 |
|
Bone Diseases
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Autosomal dominant osteopetrosis type II (ADO II) is a rare, heritable bone disorder characterized by a high bone mass and insufficient osteoclast activity.
|
24336069 |
2014 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Our screens also identified that the metabolic protein 2-aminoethanethiol dioxygenase (Ado) modulates sensitivity to TNF-mediated killing by cytotoxic lymphocytes and is required for optimal control of tumors in vivo.
|
29776993 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The objective of the study was to study the antiproliferative effects of 8-Cl-ADO on growth and proliferation in B-lymphocytes of Carney complex patients that have PKA defects and to determine whether 8-CL-ADO could be used as a therapeutic agent in the treatment of Carney complex-associated tumors.
|
19773399 |
2009 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we have predicted a 3D model structure for ADO and summarized the biological roles and the pathological consequences which are associated with the altered expression and functioning of ADO and CDO in case of cancer, neurodegenerative disorders and other human diseases.
|
28439920 |
2017 |
|
Atrial Septal Defects
|
0.010 |
Biomarker
|
group |
BEFREE |
Among the 114 patients submitted to ADO II-AS implantation at our institution, 12 received this device as off-label treatment of paravalvular leak (n = 5), sinus of Valsalva fissuration (n = 2), accessory atrial septal defect (n = 2), muscular ventricular septal defect (n = 1), bleeding bronchial artery aneurysm (n = 1) and reverse shunt due to abnormal origin of left subclavian artery from pulmonary artery (n = 1).
|
27898501 |
2017 |
|
Ventricular Septal Defects
|
0.010 |
Biomarker
|
group |
BEFREE |
The CHB that is a major challenge for closure of VSDs is less common with soft, specially designed ADO II, which does not compress the conducting system.
|
24130123 |
2017 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we have predicted a 3D model structure for ADO and summarized the biological roles and the pathological consequences which are associated with the altered expression and functioning of ADO and CDO in case of cancer, neurodegenerative disorders and other human diseases.
|
28439920 |
2017 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we have predicted a 3D model structure for ADO and summarized the biological roles and the pathological consequences which are associated with the altered expression and functioning of ADO and CDO in case of cancer, neurodegenerative disorders and other human diseases.
|
28439920 |
2017 |
|
Albuminuria
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic Association of Albuminuria with Cardiometabolic Disease and Blood Pressure.
|
30220432 |
2018 |
|
Diastolic blood pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension.
|
27618447 |
2016 |
|
Diastolic blood pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci.
|
27618448 |
2016 |
|
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Dyspnea
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
The ability to predict mortality was compared in terms of discrimination by Harrell's C (HC) index and calibration using graphical comparison among the GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2011, GOLD 2017, GOLD grade, BODE (BMI, Airflow Obstruction, Dyspnea, Exercise), updated BODE, BODEx (BMI, Airflow Obstruction, Dyspnea, Exacerbation), e-BODE (Exacerbation and BODE), ADO (Age, Dyspnea, Airflow Obstruction), COPD prognostic index (CPI), and simplified/optimized B-AE-D (BMI, Acute Exacerbation, Dyspnea) indexes.
|
31665736 |
2019 |
|
Dyspnea
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Five clusters were identified based on three PCA components, which accounted for 60% of variance of the data.Importantly, couch potatoes (i.e. the most inactive cluster) were characterised by higher BMI, lower FEV<sub>1</sub>, worse dyspnoea and higher ADO index compared to other clusters ( p < 0.05 for all).
|
28774199 |
2017 |
|
Seizures
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
All A1AR agonists were efficacious in preventing seizure and promoting survival.
|
31069755 |
2019 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Emerging evidence suggests that the adenosine (Ado) receptors may play crucial roles in tumor progression.
|
27911956 |
2016 |
|
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have reported loss-of-function mutations in the chloride channel 7 (CLCN7) gene as a cause of autosomal dominant osteopetrosis type II (ADO-II).
|
19288050 |
2009 |
|
Autosomal Dominant Osteopetrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we describe a patient who presented with a clinical picture of Autosomal Dominant Osteopetrosis type I (ADO I), in whom we could identify the first deletion in the LRP5 gene causing increased bone mass.
|
21600326 |
2011 |
|
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Autosomal dominant osteopetrosis type II (ADO II) is a rare, heritable bone disorder characterized by a high bone mass and insufficient osteoclast activity.
|
24336069 |
2014 |
|
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There are three types of osteopetrosis: autosomal recessive osteopetrosis (ARO), autosomal dominant osteopetrosis type II (ADO II), and intermediate autosomal recessive osteopetrosis (IARO).
|
21962762 |
2012 |
|
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the CLCN7 gene result in autosomal dominant osteopetrosis type II (ADO‑II), autosomal recessive osteopetrosis (ARO) and intermediate ARO (IARO).
|
30942407 |
2019 |
|
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical Significance of DXA and HR-pQCT in Autosomal Dominant Osteopetrosis (ADO II).
|
29018903 |
2018 |
|
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Novel mutations of CLCN7 cause autosomal dominant osteopetrosis type II (ADO-II) and intermediate autosomal recessive osteopetrosis (IARO) in Chinese patients.
|
26395888 |
2016 |